Ardelyx
ARDX
About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Employees: 395
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
27% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 63
22% more call options, than puts
Call options by funds: $8.49M | Put options by funds: $6.95M
1.05% more ownership
Funds ownership: 69.05% [Q1] → 70.09% (+1.05%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
8% less funds holding
Funds holding: 220 [Q1] → 203 (-17) [Q2]
19% less capital invested
Capital invested by funds: $808M [Q1] → $657M (-$151M) [Q2]
33% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 43
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Piper Sandler
Christopher Raymond
|
$9
|
Neutral
Maintained
|
6 Aug 2025 |
|
Wedbush
Laura Chico
|
$14
|
Outperform
Maintained
|
5 Aug 2025 |
|
Raymond James
Ryan Deschner
|
$12
|
Outperform
Maintained
|
5 Aug 2025 |
|
HC Wainwright & Co.
Matthew Caufield
|
$10
|
Buy
Assumed
|
18 Jun 2025 |
Financial journalist opinion
Based on 3 articles about ARDX published over the past 30 days
